KR102510784B1 - 이환형 헤테로아릴 유도체 및 이의 제조 및 용도 - Google Patents

이환형 헤테로아릴 유도체 및 이의 제조 및 용도 Download PDF

Info

Publication number
KR102510784B1
KR102510784B1 KR1020227009227A KR20227009227A KR102510784B1 KR 102510784 B1 KR102510784 B1 KR 102510784B1 KR 1020227009227 A KR1020227009227 A KR 1020227009227A KR 20227009227 A KR20227009227 A KR 20227009227A KR 102510784 B1 KR102510784 B1 KR 102510784B1
Authority
KR
South Korea
Prior art keywords
delete delete
compound
benzo
amine
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227009227A
Other languages
English (en)
Korean (ko)
Other versions
KR20220038833A (ko
Inventor
지아-닝 시앙
쉬에송 쉬
웨이 조우
Original Assignee
엑스더블유파마 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엑스더블유파마 리미티드 filed Critical 엑스더블유파마 리미티드
Publication of KR20220038833A publication Critical patent/KR20220038833A/ko
Application granted granted Critical
Publication of KR102510784B1 publication Critical patent/KR102510784B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D293/00—Heterocyclic compounds containing rings having nitrogen and selenium or nitrogen and tellurium, with or without oxygen or sulfur atoms, as the ring hetero atoms
    • C07D293/10—Heterocyclic compounds containing rings having nitrogen and selenium or nitrogen and tellurium, with or without oxygen or sulfur atoms, as the ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D293/12—Selenazoles; Hydrogenated selenazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020227009227A 2017-03-30 2017-03-30 이환형 헤테로아릴 유도체 및 이의 제조 및 용도 Active KR102510784B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2017/078873 WO2018176343A1 (en) 2017-03-30 2017-03-30 Bicyclic heteroaryl derivatives and preparation and uses thereof
KR1020197032057A KR102378845B1 (ko) 2017-03-30 2017-03-30 이환형 헤테로아릴 유도체 및 이의 제조 및 용도

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197032057A Division KR102378845B1 (ko) 2017-03-30 2017-03-30 이환형 헤테로아릴 유도체 및 이의 제조 및 용도

Publications (2)

Publication Number Publication Date
KR20220038833A KR20220038833A (ko) 2022-03-29
KR102510784B1 true KR102510784B1 (ko) 2023-03-15

Family

ID=63673949

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020227009227A Active KR102510784B1 (ko) 2017-03-30 2017-03-30 이환형 헤테로아릴 유도체 및 이의 제조 및 용도
KR1020197032057A Active KR102378845B1 (ko) 2017-03-30 2017-03-30 이환형 헤테로아릴 유도체 및 이의 제조 및 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020197032057A Active KR102378845B1 (ko) 2017-03-30 2017-03-30 이환형 헤테로아릴 유도체 및 이의 제조 및 용도

Country Status (11)

Country Link
US (4) US10640476B2 (cg-RX-API-DMAC7.html)
EP (1) EP3601235B1 (cg-RX-API-DMAC7.html)
JP (2) JP6991239B2 (cg-RX-API-DMAC7.html)
KR (2) KR102510784B1 (cg-RX-API-DMAC7.html)
CN (2) CN110709386B (cg-RX-API-DMAC7.html)
AU (1) AU2017406159B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019020464A2 (cg-RX-API-DMAC7.html)
CA (1) CA3058216C (cg-RX-API-DMAC7.html)
RU (1) RU2725886C1 (cg-RX-API-DMAC7.html)
TW (1) TWI765995B (cg-RX-API-DMAC7.html)
WO (1) WO2018176343A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
BR112021013766A2 (pt) 2019-03-01 2021-09-21 Flamel Ireland Limited Composições de gama-hidroxibutirato com farmacocinética melhorada no estado alimentado
JPWO2021070957A1 (cg-RX-API-DMAC7.html) * 2019-10-09 2021-04-15
EP3912625A1 (en) * 2020-05-20 2021-11-24 Kaerus Bioscience Limited Novel maxi-k potassium channel openers for the treatment of fragile x associated disorders
CN112321532B (zh) * 2020-11-27 2022-09-20 温州大学 一种含硒杂环化合物的制备方法
KR102545934B1 (ko) 2021-09-02 2023-06-22 경상국립대학교산학협력단 저온 인장특성이 우수한 Inconel 718 합금 적층 조형물 제조방법 및 이를 이용한 Inconel 718 합금 적층 조형물
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
CN115844910B (zh) * 2022-11-29 2025-07-04 嘉兴大学 一种预防或治疗脑胶质瘤的药物及其制备方法与应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2662695A1 (fr) 1990-06-05 1991-12-06 Rhone Poulenc Sante Amino-2 polyfluoroalcoxy-6 benzoselenazoles, leur preparation et les medicaments les contenant.

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458772B1 (en) 1909-10-07 2002-10-01 Medivir Ab Prodrugs
DE852392C (de) * 1944-08-30 1952-10-13 Hoechst Ag Verfahren zur Darstellung von Selencyanverbindungen bzw. Selenazolen von aromatischen Aminen
FR2148362A1 (en) 1971-08-11 1973-03-23 Ferlux 2-amino-(4,5-b)-oxazolopyridine cpds - with analgesic,anti-inflammato anticonvulsant,muscle relaxant and diuretic activity
FR2492258A1 (fr) * 1980-10-17 1982-04-23 Pharmindustrie Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
ES2043070T3 (es) * 1988-12-15 1993-12-16 Rhone Poulenc Sante Procedimiento para la preparacion de derivados de la benzotiazolamina-2.
US5236940A (en) * 1988-12-15 1993-08-17 Rhone-Poulenc Sante Pharmaceutical compositions, 2-benzothiazolamine derivatives, and their preparation
FR2699077B1 (fr) * 1992-12-16 1995-01-13 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de lésions neurologiques liées à des traumatismes.
FR2726271B1 (fr) * 1994-10-26 1996-12-06 Rhone Poulenc Rorer Sa Derives de 6-polyfluoroalcoxy-2-aminobenzothiazole
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
WO1999051613A1 (en) 1998-04-03 1999-10-14 Medivir Ab Prodrugs of phosphorous-containing pharmaceuticals
US6489350B1 (en) * 1999-09-15 2002-12-03 Elan Pharmaceuticals, Inc. Methods for treating neuropathic pain using heteroarylmethanesulfonamides
GB0002952D0 (en) 2000-02-09 2000-03-29 Pharma Mar Sa Process for producing kahalalide F compounds
TW200301251A (en) 2001-12-20 2003-07-01 Wyeth Corp Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands
US6867320B2 (en) 2002-02-21 2005-03-15 Asahi Kasei Pharma Corporation Substituted phenylalkanoic acid derivatives and use thereof
JP2004059452A (ja) * 2002-07-25 2004-02-26 Asahi Glass Co Ltd ペンタフルオロサルファー置換ベンズイミダゾール化合物およびその製造方法
US7582635B2 (en) * 2002-12-24 2009-09-01 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
WO2005076854A2 (en) 2004-02-04 2005-08-25 Smithkline Beecham Corporation Pyrimidinone compounds useful as kinase inhibitors
BRPI0507629A (pt) 2004-02-13 2007-07-03 Banyu Pharma Co Ltd composto, antagonista do receptor e agonista inverso do receptor da histamina h3, agente profilático ou terapêutico para uma doença metabólica, uma doença circulatória ou uma doença do sistema nervoso, ou um seu sal farmaceuticamente aceitável
MY144903A (en) 2004-06-17 2011-11-30 Novartis Ag Pyrrolopyridine derivatives and their use as crth2 antagonists
US8193211B2 (en) 2004-09-30 2012-06-05 Supernus Pharmaceuticals, Inc. Controlled release compositions of gamma-hydroxybutyrate
JP2008543915A (ja) 2005-06-21 2008-12-04 ノイロサーチ アクティーゼルスカブ 2−(フェニルアミノ)ベンズイミダゾール誘導体及び低コンダクタンスカルシウム依存性カリウムチャネルのモジュレーターとしてのそれらの使用
WO2008010223A2 (en) 2006-07-17 2008-01-24 Ramot At Tel Aviv University Ltd. Conjugates comprising a psychotropic drug or a gaba agonist and an organic acid and their use in treating pain and other cns disorders
ITTO20070665A1 (it) 2007-09-24 2009-03-25 Rottapharm Spa Derivati amidinici, tioureici e guanidinici di 2-amminobenzotiazoli e amminobenzotiazine, nuovi agenti farmacologici per il trattamento delle patologie neurodegenerative.
WO2009102462A1 (en) 2008-02-15 2009-08-20 Abbott Laboratories Thienopyrroles and pyrrolothiazoles as new therapeutic agents
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
US7863291B2 (en) 2008-04-23 2011-01-04 Bristol-Myers Squibb Company Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands
DK2278975T3 (en) 2008-05-07 2016-12-19 Cardioxyl Pharmaceuticals Inc NOVEL nitroso compounds WHICH NITROXYLDONORER AND METHODS OF USE THEREOF
MX2010013249A (es) 2008-06-04 2010-12-21 Astrazeneca Ab Derivados de tiazolo[5,4-b]piridina y oxazolo[5,4-b]piridina como agentes antibacterianos.
WO2010100144A1 (en) 2009-03-04 2010-09-10 Merck Serono S.A. Fused bicyclic compounds as inhibitors for pi3 kinase
CA2759251C (en) 2009-04-23 2017-01-03 Concert Pharmaceuticals, Inc. 4-hydroxybutyric acid analogs
KR101632318B1 (ko) * 2009-11-05 2016-06-27 재단법인 의약바이오컨버젼스연구단 벤조헤테로사이클 유도체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 암 예방 및 치료용 조성물
US20120149718A1 (en) 2010-12-14 2012-06-14 Brotherton-Pleiss Christine E Amido Compounds
BR112013020620A2 (pt) 2011-02-14 2016-10-04 Concert Pharmaceuticals Inc análogos de ácido 4-hidroxibutírico
EA201490406A1 (ru) 2011-07-29 2014-07-30 Кариофарм Терапевтикс, Инк. Модуляторы ядерного транспорта и их применение
SG11201406759YA (en) 2012-04-26 2014-11-27 Bristol Myers Squibb Co Imidazothiadiazole derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation
US9458179B2 (en) 2012-05-24 2016-10-04 Bristol-Myers Squibb Company Quinuclidine, 1-azabicyclo[2.2.1]heptane, 1-azabicyclo [3.2.1]octane, and 1-azabicyclo[3.2.2]nonane compounds as alpha-7 nicotinic acetylcholine receptor ligands
US20150210624A1 (en) 2012-08-22 2015-07-30 Concert Pharmaceuticals, Inc. Deuterated 4-hydroxybutyric acid analogs
WO2014152263A1 (en) 2013-03-15 2014-09-25 Karyopharm Therapeutics Inc. Exo olefin-containing nuclear transport modulators and uses thereof
WO2014205393A1 (en) 2013-06-21 2014-12-24 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
WO2015057884A1 (en) 2013-10-16 2015-04-23 The Regents Of The University Of California Methods for treating seizure disorders and pain
ITMI20132041A1 (it) 2013-12-06 2015-06-07 Ct Lab Farm Srl Derivati dell'acido gamma-idrossibutirrico, loro preparazione e loro uso medico.
CN104478828B (zh) 2014-12-10 2016-07-06 漳州片仔癀药业股份有限公司 2-氨基-7-取代苯并噻唑类化合物及其制备方法与用途
CN108283000B (zh) 2015-09-23 2021-04-13 凯瑞康宁生物工程(武汉)有限公司 γ-羟基丁酸的前药及其组合物和用途
US20170299609A1 (en) * 2016-04-18 2017-10-19 Wright State University Treatment of amyotrophic lateral sclerosis with sk channel activators
WO2018098472A1 (en) 2016-11-28 2018-05-31 Karyopharm Therapeutics Inc. Crm1 inhibitors for treating epilepsy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2662695A1 (fr) 1990-06-05 1991-12-06 Rhone Poulenc Sante Amino-2 polyfluoroalcoxy-6 benzoselenazoles, leur preparation et les medicaments les contenant.

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE REGISTRY [Online], CAS Registry Number: 1211588-05-4 (2010.03.19.)
Molecular Pharmacology, 2009, 제75권, 제2호, 페이지 281-295

Also Published As

Publication number Publication date
KR102378845B1 (ko) 2022-03-24
JP2020512337A (ja) 2020-04-23
RU2725886C1 (ru) 2020-07-07
US20220298127A1 (en) 2022-09-22
WO2018176343A1 (en) 2018-10-04
KR20190134711A (ko) 2019-12-04
EP3601235A4 (en) 2020-11-18
JP7291195B2 (ja) 2023-06-14
US11401249B2 (en) 2022-08-02
BR112019020464A2 (pt) 2020-04-28
US20200017456A1 (en) 2020-01-16
EP3601235C0 (en) 2026-03-04
US10640476B2 (en) 2020-05-05
CA3058216C (en) 2023-08-15
EP3601235B1 (en) 2026-03-04
AU2017406159A1 (en) 2019-11-14
CN110709386B (zh) 2022-06-07
EP3601235A1 (en) 2020-02-05
US11639337B2 (en) 2023-05-02
AU2017406159B2 (en) 2020-05-21
JP6991239B2 (ja) 2022-01-12
JP2022033921A (ja) 2022-03-02
CN115025086A (zh) 2022-09-09
CN110709386A (zh) 2020-01-17
US10882832B2 (en) 2021-01-05
US20210094925A1 (en) 2021-04-01
TW201840544A (zh) 2018-11-16
US20200181102A1 (en) 2020-06-11
TWI765995B (zh) 2022-06-01
CA3058216A1 (en) 2018-10-04
KR20220038833A (ko) 2022-03-29

Similar Documents

Publication Publication Date Title
JP7291195B2 (ja) 二環式ヘテロアリール誘導体ならびにその調製および使用
AU2019283096B2 (en) Compounds as nuclear transport modulators and uses thereof
EP3856719B1 (en) Compounds as neuronal histamine receptor-3 antagonists and uses thereof
WO2020020189A1 (en) Compounds as neurokinin-1 receptor antagonists and uses thereof
IL286373B1 (en) Protein tyrosine phosphatase inhibitor compounds and uses thereof
US10196383B2 (en) Substituted quinazoline compounds and preparation and uses thereof
CA3075954A1 (en) Novel heterocyclic compounds
JP7436630B2 (ja) アデノシン受容体拮抗薬
HK40072528A (en) Bicyclic heteroaryl derivatives and preparation and uses thereof
HK40014757A (en) Bicyclic heteroaryl derivatives and preparation and uses thereof
HK40014757B (en) Bicyclic heteroaryl derivatives and preparation and uses thereof

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 4